QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has filed a complaint against bioMérieux S.A.

QIAGEN N.V.’s QGEN fourth-quarter performance was driven by solid potential in molecular diagnostics. The company continues to progress with its test menu expansion, building a solid foundation to ...

This patent, which is one of many held by QIAGEN protecting the QuantiFERON technology, covers important innovations in QuantiFERON-TB Gold Plus that is used worldwide for TB detection.

The patent, among several owned by QIAGEN that protect the QuantiFERON technology, encompasses significant innovations in the QuantiFERON-TB Gold Plus, which is employed worldwide for tuberculosis ...

Qiagen (QGEN) announced that it has filed a complaint against bioMerieux for patent infringement. The complaint, filed in the Local Division of ...

AirHopAI today announced launch of First Office Application at Rakuten Mobile of an AI/ML-powered sustainability solution that manages MIMO antenna reconfiguration which aims to reduce Radio Access ...

Hygiene and health company Essity is today publishing its Annual Report for 2024 on essity.com. "Essity is in better shape than ever and based on the profitable platform we have created over several ...

For more information, contact [email protected]. All ELI students from a country that has been identified as high-risk must be tested for Tuberculosis using the Quantiferon test before coming to ...

QIAGEN has filed a lawsuit against bioMérieux in the German Unified Patent Court to protect its QuantiFERON technology, specifically its Europea ...